Patients with Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC.
Frontiers in Oncology（2021）
Key words
targeted therapy,immunotherapy,programmed cell death ligand-1,EGFR-tyrosine kinase inhibitors (EGFR-TKI),epidermal growth factor receptor
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined